N/A N=39 Effect of Cocoa Supplementation Peripheral and Autonomic Diabetic Neuropathy
Diabetic Neuropathies
Primary: Toronto Clinical Scoring System (TCSS) — -2.63; -1.84; 9.31; 6.89 Score on a scale — p=>0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=44 Corneal Nerves Function and Structure
Diabetic Peripheral Neuropathy
Primary: Cornea Sensitivity — 0.177; 0.293 time ratio of eyelids closed vs. open — p=<0.001
N/A N=900 Detection and Classification of Diabetic Retinopathy From Posterior Pole Images With A Deep Learning Model
Diabetic Retinopathy · Diabetic Eye Problems · Diabetic Macular Edema
Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives
N/A N=42 A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
Chemotherapy-induced Peripheral Neuropathy
Primary: Aδ:C Fiber Detection Threshold Ratio — 2.04; 1.57 ratio — p=0.05
Phase 2 N=40 Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-Induced Peripheral Neuropathy · Malignant Solid Neoplasm
Primary: Change in Chemotherapy-induced Peripheral Neuropathy (CIPN) From Baseline — 147.95; 135.82; 167.96; 148.45 percentage of change in CIPN
Phase 2 N=12 Gene Therapy for Painful Diabetic Neuropathy
Painful Diabetic Peripheral Neuropathy
Primary: Treatment-emergent Adverse Events for Participants Who Received Engensis 4 mg, 8 mg, or 16 mg — 3; 2; 2; 1 Participants
Phase 3 N=623 Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Diabetic Neuropathy, Painful
Primary: Baseline Mean Pain Score — 6.65; 6.67 units on a scale
N/A N=10 Effect Of Mesenchymal Stem Cells Transfusion on the Diabetic Peripheral Neuropathy Patients .
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
N/A N=28 Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Type 2 Diabetes · Overt Diabetic Nephropathy
Primary: Proteinuria — 2.4; 1.6; 1.2; 1.6 g/24hr
Phase 2 N=180 Efficacy and Safety Study of ARC-4558 for Management of Pain Associated With Painful Diabetic Neuropathy
Painful Diabetic Neuropathy
Primary: Change From Baseline to Week 12 in the Average Daily Pain NPRS (Numeric Pain Rating Scale) Score; mLOCF Imputation — -1.9; -2.4; -1.5; -2.7 units on a scale — p=0.168
Phase 3 N=451 A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic Neuropathy
Diabetic Neuropathy
Primary: Number of Subjects With Adverse Events (AEs) Reported Spontaneously by the Subject or Observed by the Investigator. — 11; 52; 74; 196 Participants
N/A N=182 Dual Field PEMF Therapy in Lower Extremity Painful Diabetic Distal Symmetric Peripheral Neuropathy
Diabetic Neuropathy Peripheral
Primary: Change in Pain Intensity — -1.47; -1.25 units on a scale
Phase 2 N=127 Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy
Pain · Diabetic Neuropathy
Primary: Change in Mean Numerical Rating Scale (NRS) Score From Baseline to Last 5 Days of Treatment — -2.33; -2.52 Scores on a scale
Phase 2 N=104 Safety and Efficacy Study for the Treatment of Painful Diabetic Neuropathy
Painful Diabetic Neuropathies
Primary: The Primary Study Endpoint Was the Change in Average 24-hour Pain Score From Baseline to the 6-month Follow-up. — -1.94; -2.78; -1.59 units on a scale
Phase 2 N=182 Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021)
Diabetic Neuropathy, Painful
Primary: Time to Efficacy Failure (TTEF) - Primary Responders — NA; NA Days